1672 Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.21 |
| 52 Week High | HK$2.30 |
| 52 Week Low | HK$1.21 |
| Beta | 0.64 |
| 1 Month Change | -6.92% |
| 3 Month Change | -29.65% |
| 1 Year Change | -35.98% |
| 3 Year Change | -64.41% |
| 5 Year Change | -81.12% |
| Change since IPO | -91.36% |
Recent News & Updates
Recent updates
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate
Dec 19
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Aug 23What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today
Nov 03Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth
Oct 13Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates
Aug 24Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
May 19Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts
Mar 27We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Feb 08Shareholder Returns
| 1672 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.0% | -9.1% | -2.6% |
| 1Y | -36.0% | -36.8% | 4.0% |
Return vs Industry: 1672 matched the Hong Kong Biotechs industry which returned -36.8% over the past year.
Return vs Market: 1672 underperformed the Hong Kong Market which returned 4% over the past year.
Price Volatility
| 1672 volatility | |
|---|---|
| 1672 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1672's share price has been volatile over the past 3 months.
Volatility Over Time: 1672's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
| 1672 fundamental statistics | |
|---|---|
| Market cap | HK$1.23b |
| Earnings (TTM) | -HK$156.26m |
| Revenue (TTM) | HK$61.11m |
20.1x
P/S Ratio-7.8x
P/E RatioIs 1672 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1672 income statement (TTM) | |
|---|---|
| Revenue | CN¥56.60m |
| Cost of Revenue | CN¥30.61m |
| Gross Profit | CN¥25.99m |
| Other Expenses | CN¥170.71m |
| Earnings | -CN¥144.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 45.92% |
| Net Profit Margin | -255.70% |
| Debt/Equity Ratio | 0% |
How did 1672 perform over the long term?
See historical performance and comparison